Table 2 Response rates by FLT3i exposure sequence
From: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Therapy by cohort | N | First FLT3i | Second FLT3i | Third/fourth FLT3i | P value* |
|---|---|---|---|---|---|
Number of responders/total (CRc rate) | |||||
Cohort 1 | 96 | 43/56 (77%) | 10/32 (31%) | 2/8 (25%) | – |
Single-agent FLT3i | 22 | 0/1 (0%) | 2/15 (13%) | 2/6 (33%) | – |
LIT + FLT3i | 32 | 17/22 (77%) | 4/9 (44%) | 0/1 (0%) | – |
CCT + FLT3i | 42 | 26/33 (79%) | 4/8 (50%) | 0/1 (0%) | – |
Cohort 2 | 301 | 82/183 (45%) | 19/89 (21%) | 3/29 (10%) | < 0.001 |
Single-agent FLT3i | 145 | 28/82 (34%) | 7/47 (14%) | 1/16 (6%) | 0.010 |
LIT + FLT3i | 113 | 40/74 (54%) | 10/32 (31%) | 2/7 (28%) | 0.061 |
CCT + FLT3i | 43 | 14/27 (52%) | 2/10 (20%) | 0/6 (0%) | 0.026 |